Pliant Therapeutics Engages Investors in September Events
Pliant Therapeutics, Inc. (Nasdaq: PLRX) is a clinical-stage biotechnology company focused on discovering and developing innovative therapies for fibrotic diseases. The company has recently announced its participation in several important investor events taking place in September.
Upcoming Investor Events
These events are part of Pliant's strategy to connect with investors and share updates on their therapeutic advancements:
Wells Fargo Healthcare Conference
On September 4, at 1:30 p.m. Eastern Time, executives Keith Cummings, M.D., Chief Financial Officer, and Éric Lefebvre, M.D., Chief Medical Officer, will engage in a fireside chat during the 2024 Wells Fargo Healthcare Conference. This discussion will cover the latest developments in Pliant's therapeutic offerings and outline the company's vision for the future.
H.C. Wainwright 26th Annual Global Investment Conference
Next, on September 11, Dr. Cummings and Dr. Lefebvre will again address investors in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference at 10:30 a.m. Eastern Time. They will share insights into the company’s progress and future plans.
Cantor Global Healthcare Conference
On September 17, attendees can listen to Bernard Coulie, M.D., Ph.D., President and CEO, along with Dr. Cummings and Dr. Lefebvre, at the Cantor Global Healthcare Conference at 10:20 a.m. Eastern Time. They will discuss the current pipeline and ongoing clinical trials.
Stifel Virtual Immunology and Inflammation Summit
Finally, on September 18, Dr. Coulie and Dr. Cummings will participate in a fireside chat at the Stifel 2024 Virtual Immunology and Inflammation Summit at 11:00 a.m. Eastern Time, where they will highlight innovative strategies for addressing fibrotic diseases.
Access to Live Webcasts
Investors interested in these discussions can access live webcasts of the fireside chats via the Investor Relations page on Pliant Therapeutics’ website. Additionally, recorded sessions will be available for 30 days post-event, allowing stakeholders to stay informed about all developments.
About Pliant Therapeutics
Pliant Therapeutics is at the forefront of developing therapies for fibrotic diseases. Their leading candidate, bexotegrast (PLN-74809), is an oral small molecule that selectively inhibits integrins ?vß6 and ?vß1. This drug is currently being tested for its effectiveness against idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The FDA has granted Fast Track Designation and Orphan Drug Designation for both conditions, and similar recognitions have been received from the European Medicines Agency.
Pliant is actively conducting its BEACON-IPF trial, an adaptive Phase 2b/3 study for bexotegrast, while also advancing a Phase 1 study for another promising candidate, PLN-101095, which targets solid tumors. Furthermore, Pliant has received clearance to initiate a Phase 1 study for PLN-101325, a monoclonal antibody aimed at addressing muscular dystrophies.
Ongoing Initiatives and Future Directions
As Pliant Therapeutics continues to grow its research pipeline and clinical presence, its innovative approach to treating fibrotic diseases positions the company strongly within the biotechnology sector. Participation in investor events not only enhances visibility but also fosters important discussions about the company's significant contributions to therapeutic advancements.
Contact Information
For inquiries from investors and the media, please reach out to:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
Email: ir@pliantrx.com
Frequently Asked Questions
What is Pliant Therapeutics focusing on during the September events?
Pliant Therapeutics will be discussing their innovative treatments for fibrotic diseases, including their lead drug, bexotegrast, at the investor events.
Who are the key speakers at the events?
Key speakers include Dr. Keith Cummings, CFO, Dr. Éric Lefebvre, CMO, and Dr. Bernard Coulie, President and CEO.
Are the live webcasts accessible to the public?
Yes, the live webcasts will be available through the Pliant Therapeutics Investor Relations webpage, and recordings will be archived for 30 days.
What is the primary indication for Pliant’s lead drug bexotegrast?
Bexotegrast is primarily being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).
How can I stay updated on Pliant Therapeutics’ progress?
You can stay updated by visiting their official website and following them on social media platforms.
